Table 1.
Characteristics of included studies.
| Studies | Sample size | Neoplasms | Dose | Intraoperative blood loss (mL) |
24 h blood loss (mL) |
Red blood cell transfusion unit/rate (%) |
Arterial and venous thromboembolism |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Author (Ano) | (n) | Surgery | TXA | TXA | Placebo | TXA | Placebo | TXA | Placebo | TXA (n) | Placebo (n) |
| Crescenti (2011) | 200 | Prostate | 500 mg before surgery and 250 mg.h-1 until close the skin | 1103 ± 500.8 | 1335 ± 686.5 | 22/39 | 37/67 | 2 | 3 | ||
| Celebi (2006) | 105 | Uterine cervix | 10 mg.kg-1 before surgery | 270 ± 40 | 390 ± 35 | 0 | 0 | ||||
| Lundin (2014) | 100 | Ovary | 15 mg.kg−1 before surgery | 520 (−772 to 3351) | 730 (23–3855) | 0.76 ± 1.45/15 | 1.06 ± 1.49/22 | 2 | 5 | ||
| Kulkami (2016) | 219 | Head and neck | 10 mg.kg-1 before surgery | 750 (600‒1000) | 780 (150‒ 2600) | 1000 (735‒1250) | 1110 (850‒ 1467) | 22 | 27 | 0 | 0 |
| Wu (2006) | 214 | Liver | 500 mg before surgery and 250 mg 6/6 h for 3 days | 300 (30‒ 2100) | 600 (40‒ 3410) | 0 | 17 | 0 | 0 | ||